Atlanta, GA, Jan. 23, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the first patient has been enrolled and dosed in the Phase 2 expansion portion of the Company's Acclaim-3 clinical study of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq® (atezolizumab) as maintenance therapy for patients with extensive stage small cell lung cancer (ES-SCLC).
Genprex () announced that the first patient has been enrolled and dosed in the Phase 2 expansion portion of the company’s Acclaim-3 clinical study of Reqorsa Gene Therapy in combination with Tecentriq as maintenance therapy for patients with extensive stage small cell lung cancer, or ES-SCLC. The Phase 2 expansion portion will enroll 50 patients at approximately 10 to 15 U.S. sites. The primary endpoint of the Phase 2 portion is to determine the 18-week progression-free survival rate from the time of the start of maintenance therapy with REQORSA and Tecentriq in patients with ES-SCLC. The company expects to complete enrollment of the first 25 patients in the second half of 2025 for interim analysis. The combination of Reqorsa and Tecentriq previously received the FDA’s Fast Track Designation for the treatment of the Acclaim-3 patient population, and the FDA has also granted Orphan Drug Designation to Reqorsa for the treatment of SCLC.
Comments